Biomea Fusion, Inc. Operating Lease Right-of-Use Assets
Biomea Fusion, Inc. (BMEA) had Operating Lease Right-of-Use Assets of $0 as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-03-24
- 2025-12-31: Operating Lease, Right-of-Use Asset $0.00.
- 2025-09-30: Operating Lease, Right-of-Use Asset $5.18M.
- 2025-06-30: Operating Lease, Right-of-Use Asset $5.30M.
- 2025-03-31: Operating Lease, Right-of-Use Asset $6.09M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-24 |
| 2025-09-30 | $5.18M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $5.30M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $6.09M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $6.85M 10-K · filed 2026-03-24 |
| 2024-09-30 | $7.59M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $8.31M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $9.01M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $9.71M 10-K · filed 2025-03-31 |
| 2023-09-30 | $11.81M 10-Q · filed 2023-10-30 |
| 2023-06-30 | $12.50M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $13.18M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $2.15M 10-K · filed 2024-03-28 |
| 2022-09-30 | $2.30M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $2.44M 10-Q · filed 2022-08-01 |
| 2022-03-31 | $2.58M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $2.72M 10-K · filed 2023-03-28 |
| 2021-09-30 | $2.86M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $3.04M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $129.00K 10-Q · filed 2021-05-27 |
| 2020-12-31 | $210.00K 10-K · filed 2022-02-28 |
| 2020-01-01 | $300.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |